Researchers at Boston University have found that people who live past 100 carry a distinct chemical pattern in their blood — one that sets them apart from everyone else who simply grows old.
Story Snapshot
- Centenarians have unusually high levels of certain bile acids and preserved steroid levels in their blood, forming a unique chemical fingerprint tied to extreme longevity.
- The findings come from the New England Centenarian Study (NECS), one of the longest-running longevity research programs in the world, founded in 1994.
- Scientists say these chemical patterns are linked to a lower risk of death, and could one day serve as biomarkers for measuring biological age.
- The study shows a strong correlation, but researchers have not yet proven that these chemicals directly cause long life — that distinction matters a lot.
What Researchers Actually Found in Centenarian Blood
Boston University’s Chobanian and Avedisian School of Medicine published a peer-reviewed study in June 2026 showing that centenarians — people aged 100 or older — have a measurable chemical fingerprint in their blood. Two things stand out most: unusually high levels of certain bile acids, and steroid levels that stay stable instead of declining the way they normally do with age. Both patterns are linked to a lower risk of death.
Bile acids are chemicals your liver makes to help digest fat. Most people think of them as purely digestive tools. But this research suggests they may play a much bigger role in how the body ages. Steroids, in this context, are not the kind athletes abuse — they are natural hormones your body produces. In most people, those levels drop steadily with age. In centenarians, they do not. That difference appears to be meaningful.
The Research Foundation Behind the Discovery
This study did not emerge from nowhere. It is built on decades of data from the New England Centenarian Study, which has been tracking people aged 100 and older since 1994. That long-term foundation gives the findings more weight than a one-off lab experiment. The NECS has enrolled thousands of participants over the years, making it one of the richest sources of human longevity data anywhere in the world.
Study co-author Stefano Monti, PhD, described the goal clearly: identify measurable chemical fingerprints associated with living a very long and healthy life. The researchers believe these fingerprints could eventually help doctors estimate a person’s biological age — how old your body actually is on the inside — and track whether lifestyle changes or medications are slowing the aging process down.
Why This Is Not a Cure — and Why That Matters
Here is where the honest science gets separated from the hype. The study shows that these chemical patterns exist in centenarians. It does not prove that the bile acids or steroids are the reason those people lived so long. That gap between correlation and causation is not a small technicality — it is the difference between a clue and an answer. Researchers have not yet mapped the biological pathway that would explain how these chemicals might protect against aging.
This pattern is familiar in longevity science. In 2024, a separate team found that six small RNA molecules called piwi-interacting RNAs predicted short-term survival in older adults with up to 86 percent accuracy — better than age, cholesterol, or 180 other standard health measures. But even that researcher cautioned the test was not ready for clinical use and needed confirmation in other studies. Every promising biomarker goes through this cycle: discovery, excitement, then the long grind of validation.
What Comes Next — and What Could Go Wrong
The most valuable next steps are straightforward. Researchers need to track these bile acid and steroid levels in people before they reach 100, to see if the pattern predicts longevity rather than just reflecting it. They also need to test the findings in diverse populations beyond the Boston area, since results from one geographic or ethnic group do not always hold up elsewhere. Neither of those follow-up studies exists yet.
The commercial risk is real. Once a study like this gets published, biotech firms notice quickly. The phrase “could become a biomarker” in a peer-reviewed paper is enough to spark product development. But a biomarker that predicts aging in a research cohort is not the same as a validated clinical test. Rushing a diagnostic tool to market before the science is fully confirmed is a disservice to the patients who would use it — and a pattern the longevity industry has repeated before. The findings from Boston University are genuinely exciting. They deserve careful follow-up, not a supplement label.
Sources:
sciencedaily.com, bumc.bu.edu, pmc.ncbi.nlm.nih.gov, frontlinegenomics.com
